Winst gevend schreef op 30 maart 2020 09:40:
Pharming: Anual report 30-3-2020: pag 53
Oral products for the prevention of
acute HAE attacks are also being developed and may be
approved in late 2020 for the USA.
Consequently,
Pharming may not obtain sufficient
market penetration with RUCONEST® or a sufficient
level of sales of the product to allow it to remain
profitable. For products under development, Pharming
is also exposed to the risk that a competitor may bring
a product with similar effects to the market faster than
the Company does, which may result in Pharming’s
sales of its
products to fall short of the level needed to
retain profitability.